Q32 Bio INC Schedule 13G passive stakes

Sirenia Capital Management LP and Alex Silverstein have reported a 0% beneficial ownership of Q32 Bio Inc. common stock, indicating a full divestment.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, disclosing a beneficial ownership of 5.49% in Q32 Bio Inc.

Boxer Capital Management, LLC and affiliated entities have reported beneficial ownership of 13.3% of Q32 Bio Inc.'s common stock as of June 30, 2026.

The Carlyle Group and its affiliates have reported beneficial ownership of 4.1% of Q32 Bio Inc.'s common stock as of June 18, 2026.

Biotechnology Value Fund and affiliates have reported a 9.99% beneficial ownership stake in Q32 Bio Inc. following recent equity transactions.

RA Capital Management and its affiliates have reported a 9.8% beneficial ownership stake in Q32 Bio Inc. following a recent private placement.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Q32 Bio Inc.'s common stock, primarily through exercisable warrants.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 1,256,228 shares, representing 8.59% of Q32 Bio Inc.'s common stock.

Opaleye Management Inc., along with Opaleye, L.P. and James Silverman, reported a passive beneficial ownership of 8.65% of Q32 Bio Inc.'s common stock.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a 9.9% beneficial ownership stake in Q32 Bio Inc., including shares underlying warrants.

Pfizer Inc. has reported a 2.3% beneficial ownership stake in Q32 Bio Inc., stemming from a prior investment in Homology Medicines, Inc. which merged with Q32 Bio.

Sio Capital Management, LLC has filed a Schedule 13G indicating it no longer holds any beneficial ownership in Q32 Bio Inc., reducing its stake to 0% as of March 31, 2025.

Bristol Myers Squibb Company has filed an amended Schedule 13G, reporting a 1.64% beneficial ownership stake in Q32 Bio Inc. as of December 31, 2024.

Sio Capital Management, LLC has reported a 5.73% beneficial ownership stake in Q32 Bio Inc., holding 697,413 shares as of December 31, 2024.